Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Zhonghua Liu Xing Bing Xue Za Zhi ; 38(9): 1263-1268, 2017 Sep 10.
Artículo en Chino | MEDLINE | ID: mdl-28910944

RESUMEN

Objective: To investigate the association between periconceptional folic acid supplementation and small for gestational age (SGA) birth based on maternal pre-pregnancy body mass index (BMI) and provide evidence for the development of comprehensive prevention programs on SGA birth. Methods: Between March, 2012 and September, 2016, a total of 8 523 pregnant women delivering in the First Affiliated Hospital of Shanxi Medical University were surveyed to collect the information about their demographic characteristics, folic acid supplementation before and during pregnancy and about their infants. Among their infants, 1 066 were small for gestational age (case group), 7 457 were appropriate for gestational age (AGA) (control group). Unconditional logistic regression model was used to evaluate the association between periconceptional folic acid supplementation and SGA birth in the context of different pre-pregnancy BMI. Results: The overall incidence of SGA birth was 12.51% (1 066/8 523). After adjusting the confounding factors, pre-pregnancy BMI<18.5 kg/m(2) was a risk factor for SGA birth (OR=1.22, 95%CI: 1.01-1.47), pre-pregnancy BMI≥24.0 kg/m(2) was associated with a reduced risk of SGA birth (OR=0.81, 95%CI:0.68-0.97). After adjusting confounding factors, periconceptional folic acid supplementation was a protective factor for SGA birth (OR=0.82, 95%CI: 0.68-0.98). After stratified by pre-pregnancy BMI, periconceptional folic acid supplementation was associated with the reduced risk of SGA birth in overweight group (24.0 kg/m(2)≤BMI<28.0 kg/m(2)) with OR of 0.55 (95%CI: 0.36-0.85). No significant association was observed in other groups. When examined by folic acid supplement type, periconceptional single folic acid supplementation (400 µg per tablet) was a protective factor for SGA birth (OR=0.82, 95%CI: 0.69-0.99). After stratified by pre-pregnancy BMI, periconceptional single folic acid supplementation (400 µg per tablet) was associated with the reduced risk of SGA birth in overweight groups (OR=0.56, 95%CI: 0.36-0.86). No association was observed between periconceptional folic acid containing multivitamin supplementation and SGA birth. Conclusions: Periconceptional folic acid supplementation (400 µg) was associated with reduced risk of SGA birth in women with pre-pregnancy BMI≥24.0 kg/m(2) and<28.0 kg/m(2). No association between folic acid supplementation and SGA was observed in other groups. This study suggests that pre-pregnancy BMI might modify the influence of folic acid supplementation on the risk of SGA birth.


Asunto(s)
Índice de Masa Corporal , Suplementos Dietéticos , Desarrollo Fetal/efectos de los fármacos , Ácido Fólico/farmacología , Recién Nacido Pequeño para la Edad Gestacional , China/epidemiología , Femenino , Ácido Fólico/administración & dosificación , Ácido Fólico/efectos adversos , Edad Gestacional , Humanos , Recién Nacido , Parto , Embarazo , Resultado del Embarazo , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA